🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎉Tri-state Obesity Society is hosting a free dinner event on 4/10 6-8PM ET in Connecticut with an expert panel on the #Business of #Obesity #Medicine ft. leaders Neil Floch MD Angela Fitch,MD Devika Umashanker Priya Jaisinghani, MD, DABOM RSVP 👉 tristateobesitysociety.org/event-details-…

So excited to have this all ⭐️ panel for this event! Tri-state Obesity Society

🔬 Lp(a) Awareness Day 2025! ❤️ 🧐 1 in 5 people are at higher risk of heart attack & stroke due to high Lp(a)—yet most aren’t tested! 📌 Why it matters: ✅ Genetic (>90%) & a causal ASCVD risk factor ✅ Test at least once (EAS guidelines) ✅ Personalize risk reduction

This looks so good!! And so many of my favs are on this panel! 👏🏻👏🏻 Beverly G. Tchang, MD Priya Jaisinghani, MD, DABOM Neil Floch MD Angela Fitch,MD

I promise it will be entertaining because I will be moderating ⁦Tri-state Obesity Society⁩ - a free dinner event on 4/10 6-8PM ET in Connecticut with an expert panel on the #Business of #Obesity #Medicine Neil Floch MD Angela Fitch,MD Devika Umashanker Priya Jaisinghani, MD, DABOM tristateobesitysociety.org/event-details-…

❤️ Breaking News for American Heart Month! ❤️ The SOUL trial brings key insights for diabetes & heart health! ❣️🔥 👥 9,650 participants | 50+ yrs with T2D + ASCVD, CKD, or both 📉 Oral semaglutide ⬇️ MACE by 14%! (HR 0.86) ✅ Now proven cardioprotective! 💬 Thoughts? #ACC25

🚶‍♂️💉 Can GLP-1 RAs improve walking distance in PAD + T2D? 🌎 PAD affects 230M+ people The STRIDE trial explored semaglutide’s impact. 📊 729 patients (median age: 68, 59% BMI <30) 💉 1 mg #semaglutide vs. placebo 📈 +40m walking distance and QoL improvement #ACC25 #lancet

A message from Obesity Medicine Association past PRESIDENT and #OAC board member Angela Fitch,MD: IT IS TIME for #GLP1 #obesity medication pharmaceutical producers to: #betheHERO #betheHERO! Cut the cost to $299 a month and Increase access to care!

🚨 Big news in T2D + obesity care! Orforglipron, the 1st oral GLP-1 RA, hit key Phase 3 goals: ✅ A1C ↓ up to 1.6% ⚖️ Weight ↓ up to 15.8 lbs (7.6%) ⭐ 65% hit A1C ≤6.5% No food/water restrictions. Once-daily pill. Game changer? #ACHIEVE1 🔗 tinyurl.com/ykp8xpkd

💊 #Orforglipron oral small molecule GLP-1 shows: 👉 A1C ↓ up to 1.6% 👉 Weight ↓ up to 7.9% 👉 Safety profile ⬅️ consistent with injectable GLP-1s 📅 Data from ACHIEVE-1 just dropped 👀 Excited for full results at #ADA2025! #GLP1 #T2D #CKMsyndrome investor.lilly.com/node/52266/pdf

BIG news in obesity & diabetes care! I shared my thoughts with CNN Jen Christensen 🙏🏻 Eli Lilly’s oral GLP-1, orforglipron, could be a game-changer: ✅ Oral ✅ No strict pre-med rules ✅ Easier to make = fewer shortages ✅ No refrigeration 🔗amp.cnn.com/cnn/2025/04/17… #GLP1

#MASLD Dr Sandeep Rai M Shafi Kuchay Idrees Mubarik Dr ABM Kamrul Hasan Dr. Deep Dutta Priya Jaisinghani, MD, DABOM Lori Shemek, PhD Sandeep Tak MD(AIIMS Delhi), FACE Dr Lakshmi Nagendra MD,DM (ENDO) Unnikrishnan AG

🍽️ Not everyone can choose healthy food — and that’s a public health issue. #FoodInsecurity is deeply linked to #MASLD, as millions face food deserts, ultra-processed options, or high costs that make healthy eating nearly impossible. In this video by Jeffrey V. Lazarus, Chair of the

Thank you Christina Farr and Leah Rosenbaum for making space for an important conversation surrounding the role of GLP-1s in women’s health. Check out my insights 🙏🏻✨

Priya Jaisinghani, MD, DABOM is moderating a panel Digital Health New York on the Use of AI in Weight Management & Maintenance

We renamed a disease—not for science, but for people. 🩺 Proud to co-author the People-First Liver Charter alongside greats in Nature Portfolio 🔗 nature.com/articles/s4159… Words can heal. Let’s end stigma in MASLD/MASH—across every specialty. 🌍💬

🚨 Win for #ObesityCare! 🚨 On 6/10 AMA passed a resolution to expand AOM coverage & stop insurer rules forcing GLP-1s through third parties. ⛔💉 Faster access for patients, less red tape for providers. Obesity is a disease—let’s treat it like one. 🧬 #advocacy

🔥 Hot off the press: #Lilly expands single-dose #Zepbound options! 💉 12.5 & 15 mg vials available July 7 💰 $499/month via #LillyDirect 📦 Patient shipments start early Aug 👏 win for increased access 🔗 investor.lilly.com/news-releases/…

🔥 Hot from #ADA2025: Can we cut fat & keep lean mass? 💪 The BELIEVE trial (semaglutide + bimagrumab) showed more VAT loss, 🔥83% drop in hsCRP, adiponectin ↑ & better DBP/HbA1c vs semaglutide alone. Game-changer? #GLP1 #ObesityCare #BELIEVE #Endocrinology#ADA2025 #bimagrumab